Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.

abstract：INTRODUCTION:Studies in vitro and in vivo have identified several peptides that are potentially useful in treating systemic lupus erythematosus (SLE). The rationale for their use lies in the cost-effective production, high potency, target selectivity, low toxicity, and a peculiar mechanism of action that is mainly base...

journal_title：Expert opinion on investigational drugs

authors： Talotta R,Atzeni F,Laska MJ

更新日期：2020-08-01 00:00:00

abstract：:The Kunitz-type proteinase inhibitor, tissue factor pathway inhibitor (TFPI), is the only endogenous inhibitor of the tissue factor (TF)-mediated coagulation pathway that plays a dominant role in normal haemostasis. TFPI exerts its action by binding to factor Xa (FXa) forming a TFPI-FXa complex that then, in a second ...

journal_title：Expert opinion on investigational drugs

authors： Kaiser B,Hoppensteadt DH,Fareed J

更新日期：1998-07-01 00:00:00

abstract：BACKGROUND:Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop legal blindness. Until recently, few treatment options existed for treatment of neovascular AMD. The a...

journal_title：Expert opinion on investigational drugs

authors： Dixon JA,Oliver SC,Olson JL,Mandava N

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:With 170 million people infected worldwide and an inadequate current standard of care, hepatitis C virus (HCV) infection represents a major unmet medical need. Multiple companies are working on the discovery and development of specific HCV antiviral drugs, including inhibitors of HCV polymerase, protease and...

journal_title：Expert opinion on investigational drugs

authors： Koev G,Kati W

更新日期：2008-03-01 00:00:00

abstract：:The fact that PPAR-gamma is expressed dramatically higher in fat, regulating gene transcription in response to small lipophilic ligands, supports an essential role of increased lipophilicity for those ligands. On the other hand, the skepticism concerning high lipophilicity as a characteristic associated with undesirab...

journal_title：Expert opinion on investigational drugs

authors： Giaginis C,Theocharis S,Tsantili-Kakoulidou A

更新日期：2007-04-01 00:00:00

abstract：:Two methods of using tumour located enzymes have been described. These are antibody directed enzyme prodrug therapy (ADEPT) and macromolecule directed enzyme prodrug therapy (MDEPT), where the tumour located enzyme converts a non-toxic prodrug into a cytotoxic drug at tumour sites. The alternative use of tumour locate...

journal_title：Expert opinion on investigational drugs

authors： Bagshawe KD,Burke PJ,Knox RJ,Melton RG,Sharma SK

更新日期：1999-02-01 00:00:00

abstract：BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

journal_title：Expert opinion on investigational drugs

authors： Poulakou G,Giamarellou H

更新日期：2008-05-01 00:00:00

abstract：UNLABELLED:IMPORTANCE OF THIS FIELD: Microtubule-inhibiting drugs are among the most commonly prescribed agents in the combat against cancer, though the clinical use of these drugs is limited by acquired resistance, risk of hypersensitivity reactions and intolerable toxicity. With progress in our understanding of cytos...

journal_title：Expert opinion on investigational drugs

authors： Chen SM,Meng LH,Ding J

更新日期：2010-03-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Curcumin has been investigated in preclinical and translational stroke models because of its pleiotropic 'neuroprotective' activities. Since curcumin has poor blood-brain barrier (BBB) penetration following acute administration, creative medicinal chemistry has been used to modify the parent cur...

journal_title：Expert opinion on investigational drugs

authors： Lapchak PA

更新日期：2011-01-01 00:00:00

abstract：:The annual meeting of the American Diabetes Association was held in Boston, MA. There were over 6500 participants, one-third from overseas, and 1103 papers were presented. Abstracts from the meeting have been published, from which abstract numbers are given below, e.g., (A141). Considerable progress has been made in u...

journal_title：Expert opinion on investigational drugs

authors： Colca J

更新日期：1997-08-01 00:00:00

abstract：:Therapeutic angiogenesis is a novel approach to the treatment of ischaemic or occlusive coronary and peripheral vascular disease. The therapeutic concept is based on the restoration of distal blood flow by the enlargement of existing vessels and tissue perfusion by the induction of new capillaries. Initial studies hav...

journal_title：Expert opinion on investigational drugs

authors： Tarzami ST,Singh JP

更新日期：2004-10-01 00:00:00

abstract：:Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need fo...

journal_title：Expert opinion on investigational drugs

authors： Soeiro MN,De Souza EM,Stephens CE,Boykin DW

更新日期：2005-08-01 00:00:00

abstract：INTRODUCTION:Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. AREAS COVERED:We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgk...

journal_title：Expert opinion on investigational drugs

authors： Chang A,Schlafer D,Flowers CR,Allen PB

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate ...

journal_title：Expert opinion on investigational drugs

authors： Chi KN,Zoubeidi A,Gleave ME

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Dasatinib is a novel tyrosine kinase inhibitor with activity against the Src family kinases. The Src pathway is active in breast cancer and has been shown to promote cell proliferation, invasiveness, and metastases. Preclinical data support the use of dasatinib to inhibit breast cancer cell growth, modulat...

journal_title：Expert opinion on investigational drugs

authors： Scher KS,Somlo G

更新日期：2013-06-01 00:00:00

abstract：:Introduction: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other m...

journal_title：Expert opinion on investigational drugs

authors： Ivy SP,Kunos CA,Arnaldez FI,Kohn EC

更新日期：2019-09-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Antiangiogenic strategies are affording considerable interest and have become a major milestone in therapeutics of various adult cancers. However, progress has been slow to expand such therapies to patients with pediatric solid malignancies. AREAS COVERED IN THIS REVIEW:This review discusses th...

journal_title：Expert opinion on investigational drugs

authors： Taylor M,Rössler J,Geoerger B,Vassal G,Farace F

更新日期：2010-07-01 00:00:00

abstract：INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

journal_title：Expert opinion on investigational drugs

authors： Elicin O,Ozsahin M

更新日期：2016-06-01 00:00:00

abstract：:Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

journal_title：Expert opinion on investigational drugs

authors： Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

更新日期：2000-11-01 00:00:00

abstract：BACKGROUND:Despite exciting progress and growth in the understanding of molecular and cellular mechanisms of chronic pain, osteoarthritis (OA) pain remains a challenging clinical entity to treat. There is an emerging diversity of algogenic mechanisms suggesting heterogeneity in pain aetiology in the OA patient populati...

journal_title：Expert opinion on investigational drugs

authors： Read SJ,Dray A

更新日期：2008-05-01 00:00:00

abstract：:Risperidone (Risperdal) is a benzisoxazole derivative with a high affinity for serotonin 5-HT2 and dopamine D2 receptors, and some affinity for alpha- adrenergic, histamine H1 and dopamine D1 receptors. It has no anticholinergic effects. Early studies demonstrated risperidone to be an effective medication for psychoti...

journal_title：Expert opinion on investigational drugs

authors： Keks NA,Culhane C

更新日期：1999-04-01 00:00:00

abstract：:The clinical use of cannabinoids is currently a topic of interest not exclusively, but most importantly, concerning different areas of pain therapy. One of the major obstacles in developing clinically acceptable compounds is the cannabimimetic side-effect profile of delta-9-tetrahydrocannabinol (THC) and other cannabi...

journal_title：Expert opinion on investigational drugs

authors： Karst M,Wippermann S

更新日期：2009-02-01 00:00:00

abstract：INTRODUCTION:In 2010, about 8.8 million new cases of tuberculosis were recorded and 1.1 million people died of tuberculosis worldwide. Although numbers are in decrease since 2006, tuberculosis still represents a global issue and a major public health threat, due to appearance of multidrug-resistant and extensively drug...

journal_title：Expert opinion on investigational drugs

authors： Engohang-Ndong J

更新日期：2012-12-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Aspirin, an irreversible inhibitor of thromboxane A(2) production, in combination with clopidogrel, an inhibitor of PY(12) ADP platelet receptors, represents the current standard-of-care of antiplatelet therapy for patients with acute coronary syndrome and those undergoing percutaneous coronary ...

journal_title：Expert opinion on investigational drugs

authors： Tomasello SD,Angiolillo DJ,Goto S

更新日期：2010-12-01 00:00:00

abstract：:Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance a...

journal_title：Expert opinion on investigational drugs

authors： Boos LA,Leslie I,Larkin J

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

journal_title：Expert opinion on investigational drugs

authors： Welsh N

更新日期：2012-11-01 00:00:00

abstract：INTRODUCTION:Subjects with atrial fibrillation are at risk of thromboembolic events. The vitamin K antagonists (e.g., warfarin) are useful at preventing coagulation in atrial fibrillation, but are difficult to use. One of the FXa inhibitors, oral apixaban, has been tested as an anticoagulant in atrial fibrillation. AR...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN. Of these, ruxolitinib ha...

journal_title：Expert opinion on investigational drugs

authors： Tam CS,Verstovsek S

更新日期：2013-06-01 00:00:00

abstract：:Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exog...

journal_title：Expert opinion on investigational drugs

authors： Boerrigter G,Burnett JC Jr

更新日期：2004-06-01 00:00:00

abstract：INTRODUCTION:Patients with myelofibrosis (MF) have no effective treatment option after the failure of approved JAK inhibitor (JAKi) therapy. Non-JAK inhibitors (non-JAKi) that target non-canonical molecular pathways are undergoing clinical evaluations to optimize efficacy and/or to reduce hematological toxicity of JAKi...

journal_title：Expert opinion on investigational drugs

authors： Bankar A,Gupta V

更新日期：2020-05-01 00:00:00